• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

酶替代疗法对晚发型庞贝病骨密度的影响。

Effects of enzyme replacement therapy on bone density in late onset Pompe disease.

作者信息

Avanti Mahima, Martin Angela, Columbres Rod Carlo, Mozaffar Tahseen, Kimonis Virginia

机构信息

Division of Genetics, Department of Pediatrics, University of California - Irvine, Orange, CA 92697, United States of America.

Division of Neuromuscular Diseases, Department of Neurology, University of California- Irvine, 200 S. Manchester Ave., Suite 206, Orange, CA, United States of America.

出版信息

Mol Genet Metab. 2023 Nov;140(3):107644. doi: 10.1016/j.ymgme.2023.107644. Epub 2023 Jun 28.

DOI:10.1016/j.ymgme.2023.107644
PMID:37515933
Abstract

Pompe disease is an autosomal recessive disorder caused by a deficiency of α-glucosidase, resulting in the accumulation of glycogen in smooth, cardiac, and skeletal muscles, leading to skeletal muscle dysfunction, proximal muscle weakness, and early respiratory insufficiency. Although many patients exhibit decreased bone mineral density (BMD) and increased fractures, there is currently no official protocol for surveillance and management of osteoporosis and osteopenia in late onset Pompe disease (LOPD). Enzyme replacement therapy (ERT) has therapeutic effects on muscle function; however, very few studies report on the effect of ERT on bone mineralization in LOPD patients. Our study included 15 Pompe patients from 25 to 76 years of age on ERT for variable durations. Progressive impact of ERT on BMD of the hips and spine, and the frequency of osteopenia or osteoporosis was studied using DEXA scanning, and correlations were made with age of initiation of ERT, duration of ERT and six-minute walk test. We found a significant positive correlation between the age of ERT initiation and age of the subject, with increases in the Z-scores for the femur and lumbar region. Females had a significantly higher risk for developing osteoporosis compared to males. These results highlight the significance of ERT on reducing progression of osteoporosis in LOPD patients.

摘要

庞贝病是一种常染色体隐性疾病,由α-葡萄糖苷酶缺乏引起,导致糖原在平滑肌、心肌和骨骼肌中蓄积,进而导致骨骼肌功能障碍、近端肌无力和早期呼吸功能不全。尽管许多患者表现出骨密度(BMD)降低和骨折增加,但目前尚无针对晚发型庞贝病(LOPD)患者骨质疏松和骨质减少的监测及管理的官方方案。酶替代疗法(ERT)对肌肉功能有治疗作用;然而,很少有研究报道ERT对LOPD患者骨矿化的影响。我们的研究纳入了15名年龄在25至76岁之间接受不同时长ERT治疗的庞贝病患者。使用双能X线吸收法扫描研究ERT对髋部和脊柱骨密度的渐进影响以及骨质减少或骨质疏松的发生率,并将其与ERT开始年龄、ERT持续时间和六分钟步行试验进行相关性分析。我们发现ERT开始年龄与受试者年龄之间存在显著正相关,股骨和腰椎区域的Z值增加。与男性相比,女性患骨质疏松症的风险显著更高。这些结果凸显了ERT对降低LOPD患者骨质疏松进展的重要性。

相似文献

1
Effects of enzyme replacement therapy on bone density in late onset Pompe disease.酶替代疗法对晚发型庞贝病骨密度的影响。
Mol Genet Metab. 2023 Nov;140(3):107644. doi: 10.1016/j.ymgme.2023.107644. Epub 2023 Jun 28.
2
Improvement of bone mineral density after enzyme replacement therapy in Chinese late-onset Pompe disease patients.中国晚发型庞贝病患者酶替代治疗后骨密度的改善
BMC Res Notes. 2017 Jul 28;10(1):351. doi: 10.1186/s13104-017-2681-y.
3
Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).短时间到长时间酶替代疗法(ERT)对晚发性庞贝病(LOPD)骨骼肌组织的影响。
Neuropathol Appl Neurobiol. 2018 Aug;44(5):449-462. doi: 10.1111/nan.12414. Epub 2017 Jul 4.
4
The emerging phenotype of late-onset Pompe disease: A systematic literature review.晚发型庞贝病的新出现表型:一项系统文献综述。
Mol Genet Metab. 2017 Mar;120(3):163-172. doi: 10.1016/j.ymgme.2016.12.004. Epub 2016 Dec 11.
5
Body composition and 6 minute walking ability in late-onset pompe disease patients after 9 years of enzyme replacement therapy.接受酶替代治疗 9 年后晚发型庞贝病患者的身体成分和 6 分钟步行能力。
Int J Neurosci. 2022 Jul;132(7):699-705. doi: 10.1080/00207454.2020.1835902. Epub 2020 Oct 20.
6
Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.接受阿糖苷酶α治疗的晚发型庞贝病患者的前瞻性探索性肌肉活检、影像学及功能评估:EMBASSY研究
Mol Genet Metab. 2016 Sep;119(1-2):115-23. doi: 10.1016/j.ymgme.2016.05.013. Epub 2016 May 19.
7
White matter lesions in treated late onset Pompe disease are not different to matched controls.治疗后的晚发性庞贝病的白质病变与匹配对照组无差异。
Mol Genet Metab. 2019 Jun;127(2):128-131. doi: 10.1016/j.ymgme.2019.05.007. Epub 2019 May 14.
8
Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.晚发型庞贝病酶替代治疗期间的呼吸功能:纵向病程、预后因素以及从诊断到开始治疗的时间影响
J Neurol. 2020 Oct;267(10):3038-3053. doi: 10.1007/s00415-020-09936-8. Epub 2020 Jun 10.
9
Safety and efficacy of alternative alglucosidase alfa regimens in Pompe disease.替代型阿糖苷酶α方案治疗庞贝病的安全性和有效性
Neuromuscul Disord. 2015 Apr;25(4):321-32. doi: 10.1016/j.nmd.2014.12.004. Epub 2014 Dec 19.
10
Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families.晚发型庞贝病中自噬和非自噬基因的罕见变异:两个意大利家族中其疾病修饰作用的提示
Int J Mol Sci. 2021 Mar 31;22(7):3625. doi: 10.3390/ijms22073625.

引用本文的文献

1
Bone disease and osteoporosis associated with Pompe disease.与庞贝病相关的骨病和骨质疏松症。
JBMR Plus. 2025 Apr 3;9(5):ziaf045. doi: 10.1093/jbmrpl/ziaf045. eCollection 2025 May.